Kirloskar Oil Engines Limited (KOEL) announced its unaudited financial results, reporting a 35% year-on-year increase in standalone net sales, exceeding ₹1,500 Crore for Q2 FY26. Standalone net profit increased by 44% year-on-year to ₹141 Crore. The company achieved its highest-ever H1 sales of ₹3,027 crore. The B2C operations were strategically restructured and transferred to La-Gajjar Machineries Private Limited.

Financial Highlights for Q2 FY26

Kirloskar Oil Engines Limited (KOEL) has announced a strong financial performance for the second quarter of fiscal year 2026. Key highlights include:

• Net sales reached ₹1,593 Cr, a 35% increase compared to ₹1,184 Cr in Q2 FY25.
• EBITDA surged to ₹214 Cr, a 45% increase from ₹148 Cr in Q2 FY25.
• EBITDA margin stood at 13.4%, up from 12.4% in Q2 FY25.
• Net profit soared to ₹141 Cr, a 44% increase from ₹98 Cr in Q2 FY25.
• Cash and cash equivalents totaled ₹475 Cr.

Consolidated Financial Performance

The consolidated financial results also reflect strong growth:

• Revenue from continuing operations reached ₹1,948 Cr, a 30% increase from ₹1,499 Cr in Q2 FY25.
• Net profit from continuing operations increased to ₹159 Cr, a 51% increase from ₹106 Cr in Q2 FY25.

H1 FY26 Performance (Standalone)

The company’s performance for the first half of FY26 demonstrates continued growth:

• Net sales amounted to ₹3,027 Cr, a 20% increase from ₹2,518 Cr in H1 FY25.
• EBITDA reached ₹405 Cr, a 25% increase from ₹323 Cr in H1 FY25.
• EBITDA margin was 13.3%, up from 12.7% in H1 FY25.
• Net profit increased to ₹264 Cr, a 23% increase from ₹215 Cr in H1 FY25.

H1 FY26 Performance (Consolidated)

• Revenue from continuing operations was ₹3,712 Cr compared to ₹3,130 Cr. This represents a 19% increase.
• Net profit from continuing operations was ₹293 Cr compared to ₹238 Cr a 23% increase.

Strategic Restructuring

On October 10, 2025, KOEL announced a strategic restructuring, transferring its B2C operations to its wholly-owned subsidiary, La-Gajjar Machineries Private Limited, through a slump sale. This move aims to sharpen the company’s focus and align with its long-term strategic vision.

Source: BSE

Multi Commodity Exchange (MCX) reported strong Q2 FY26 results with a 29% increase in total revenue to INR401 crores. EBITDA rose by 32% to INR270 crores, and profit after tax increased by 29% to INR197 crores. Average Daily Turnover (ADT) reached INR4.11 lakh crores. The MCX BULLDEX index options were launched in October.

Financial Performance Highlights

Multi Commodity Exchange of India Limited (MCX) announced its Q2 FY26 financial results, showcasing significant growth. Total consolidated revenue reached INR401 crores, a 29% increase compared to the same quarter last year. The company’s EBITDA increased by 32% to INR270 crores, while profit after tax grew by 29% to INR197 crores.

Key Operational Metrics

The Average Daily Turnover (ADT) has risen to INR4.11 lakh crores, a substantial increase from INR2.02 lakh crores in the previous year, reflecting robust market activity and increased stakeholder confidence.

Product Launches and Developments

MCX has focused on expanding its product offerings, including launching further variants in the bullion sector. Monthly options on silver (30 kg contract and mini 5 kg contract) were introduced. Fresh future contracts in cardamom and Nickel were also launched. The MCX BULLDEX index options were launched in October.

Technology Enhancements

MCX is committed to enhancing its technology infrastructure to support market volumes and growth. Steps have been taken to address and prevent recurrence of technical issues experienced in October. Investments in technology are planned to ensure continuous upgrades and capacity to support future growth.

Strategy and Outlook

The company aims to reinforce its position as a leading commodity derivative exchange by expanding its product suite and deepening market participation. MCX anticipates that the enhanced technology and diverse product range will drive future growth.

Segment Revenue

In Q2, revenue from futures was INR114 crores and from options, it was INR223 crores.

Source: BSE

Bajaj Finserv has announced key performance indicators for its insurance subsidiaries for the month of October 2025. Bajaj General Insurance reported a gross direct premium underwritten of ₹1910.11 crore. Bajaj Life Insurance recorded new business premium totaling ₹1,135.39 crore for the month, and ₹7,462.57 crore for the period from April 2025 to October 2025.

Bajaj General Insurance Performance

For the month of October 2025, Bajaj General Insurance Limited reported a gross direct premium underwritten of ₹1910.11 crore. The up-to-the-month figure for October 2025 stands at ₹13,464.46 crore.

Bajaj Life Insurance New Business Update

Bajaj Life Insurance Limited reported the following new business figures:

October 2025 Premiums

• Individual single premium: ₹69.13 crore
• Individual non-single premium: ₹516.06 crore
• Group single premium: ₹521.47 crore
• Group yearly renewable premium: ₹28.73 crore

April-October 2025 Premiums

• Individual single premium: ₹427.98 crore
• Individual non-single premium: ₹3,583.54 crore
• Group single premium: ₹3,053.79 crore
• Group yearly renewable premium: ₹397.26 crore

The total new business premium for Bajaj Life Insurance Limited for October 2025 was ₹1,135.39 crore. The total for the period from April 2025 to October 2025 reached ₹7,462.57 crore.

Source: BSE

Jupiter Wagons has received monitoring agency reports for the quarter ending September 30, 2025, related to its Qualified Institutional Placements (QIPs) and preferential issue of warrants. The reports, provided by Care Ratings Limited, indicate that proceeds from these issues have not been fully utilized as of the reporting period. The funds are earmarked for various purposes, including capacity enhancement, working capital, and inorganic growth. A revised object for capex was approved on April 18, 2025.

QIP and Warrant Monitoring

Monitoring agency reports have been issued for Jupiter Wagons concerning Qualified Institutional Placements (QIPs) and preferential warrant issues, with the review period ending on September 30, 2025. These reports, provided by Care Ratings Limited, assess the appropriate use and allocation of raised funds for specific corporate objectives.

Fund Utilization Status

The reports indicate that funds raised through QIPs, intended to enhance capacity at the Bandel foundry, have experienced delays in utilization. While ₹6.36 crore has been utilized, a substantial ₹43.64 crore remains unutilized. The reasons cited are delays, which led to a revised plan to utilise the unutilised idle QIP fund for the same, a revised plan to utilize the funds was approved by shareholders on April 18, 2025. There have been no utilizations for the reporting quarter.

Preferential Issue of Warrants

Funds raised through the preferential issue of warrants, intended for investment in a subsidiary namely, Jupiter Tatravagonka Railwheel Factory Pvt. Ltd, have been partially deployed. Of the ₹135 crore raised, ₹33.75 crore (25%) has been utilized, while the remaining balance is yet to be deployed.

Unutilized Funds Deployment

The company is holding unutilized funds in various fixed deposits with banks such as ICICI Bank, Federal Bank and Yes Bank and Kotak and SBI mutual funds. The total held in those deposits is ₹220.82 crore. After accounting for interest income of ₹21.86 crore, the unutilized amount is ₹198.96 crore.

Source: BSE

Clean Science and Technology Limited announced its Q2 FY26 results, with revenues reaching INR206 crores on a standalone basis. EBITDA margins remained resilient at 44%. The company commercialized HALS 2020, improving the HALS portfolio’s material margin to 35%. Approximately INR150 crores was invested in CFCL during the first half year. Monthly run rate volumes for the HALS segment in Q2 FY26 averaged approximately 260 tons, representing a 25% growth.

Financial Performance Overview

Clean Science and Technology Limited reported a revenue of INR206 crores on a standalone basis for Q2 FY26, a decrease of 5% sequentially and 8% year-on-year, primarily due to lower sales in certain established products. The company’s EBITDA margins remained strong at 44% for the quarter. Standalone EBITDA was reported at INR90 crores, a 10% decrease Q-o-Q and 5% decrease Y-o-Y. The company’s standalone PAT stood at INR65 crores, 15% lower Q-o-Q and 4% lower Y-o-Y, impacted primarily by forex losses.

Segmental Highlights

The company successfully commercialized HALS 2020, enriching its product portfolio, and improved the material margin for the HALS portfolio to 35% from 31% due to improved raw material costs. The HALS segment saw its monthly run rate volumes average to approximately 260 tons per month in Q2, reflecting a growth of over 25% compared to the previous quarter.

Capex and New Products

Clean Science invested approximately INR150 crores in its subsidiary, CFCL, during the first half of the year. Performance Chemical 1 is undergoing chemical trials with satisfactory results, with commercialization expected this month. The company also successfully commercialized barbituric acid by repurposing an existing facility and expanded capacities for some food-grade antioxidants.

Market Dynamics and Outlook

Lower sales during the quarter were attributed to price declines in end products due to competition from Chinese suppliers and demand uncertainty in end markets. The company believes these trends represent a mix of tariff impacts and demand slowdown in some end industries, influencing customer purchasing behavior. Looking ahead, the company aims to work closely with customers, addressing price reductions where needed to maintain competitiveness and market share.

Source: BSE